

Contents

Volume 1

Prologue *XXV*

Dedication *XXIX*

Foreword *XXXI*

Foreword *XXXV*

Quotes *XXXVII*

Executive Summary *XLI*

List of Contributors *CXXIII*

Introduction

Current Status of Biopharmaceuticals: Approved Products and Trends in Approvals 1

Gary Walsh

- 1 What are Biopharmaceuticals? 2
- 2 A Global Snapshot 2
- 3 Upstream and Downstream Processing 3
- 4 Trends in Approvals 6
- 5 Declining Number of Approvals 8
- 6 Products Approved for Human Use 9
- 7 Products Approved for Veterinary Use 25
- 8 Likely Future Directions 27
- 9 Concluding Remarks 33

Part I Biopharmaceuticals Used in Molecular Medicine**From Genome to Clinic – Correlation Between Genes, Diseases and Biopharmaceuticals 37**

- 1 Beginning to Understand the End of the Chromosome 37**
Thomas R. Cech
 - 1.1 Introduction 37
 - 1.2 Telomere Terminal Transferase 38
 - 1.3 Telomerase Contains an Essential RNA 38
 - 1.4 Finally, the Protein: Telomerase Reverse Transcriptase 39
 - 1.5 Current Picture of Telomerase 40
 - 1.6 Regulation of Telomerase 42
 - 1.7 Cellular Immortality 44
 - 1.8 Cancer 44

- 2 The Role of Pharmacogenetics/Pharmacogenomics in Drug Development and Regulatory Review: Current Status 49**
Shiew-Mei Huang and Lawrence J. Lesko
 - 2.1 Introduction 50
 - 2.2 Variability in Drug Response 50
 - 2.3 Drug-metabolizing Enzymes and Transporters 52
 - 2.4 Applications of Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Review 54
 - 2.5 Determination of Different Genotype Groups based on Known Valid and Probable Valid Biomarkers 56
 - 2.6 Drug Interactions 60
 - 2.7 Voluntary versus Required Submissions 60
 - 2.8 Labeling Implications 63
 - 2.9 Conclusion 64

- 3 Large-scale Detection of Genetic Variation: The Key to Personalized Medicine 71**
Joerg Geistlinger and Peter Ahnert
 - 3.1 Genetic Variation, Disease Susceptibility and Drug Response 73
 - 3.2 Pharmacogenetics and Pharmacogenomics 74
 - 3.3 Personalized Medicine 76
 - 3.4 SNPs in Clinical Applications 78
 - 3.5 Strategies in SNP Discovery 80
 - 3.6 SNP Technologies 83
 - 3.7 Polydimensional SNP-Chips: The Array-On Technology 88
 - 3.8 Outlook 93

- 4 A Systems Biology Approach to Target Identification and Validation for Human Chronic Disease Drug Discovery 99**
Bonnie E. Gould Rothberg, Carol E. A. Peña, and Jonathan M. Rothberg
 - 4.1 Limitations in the Chronic Disease Drug Discovery Process 100

- 4.2 Creating the Pharmaceutically Tractable Genome 104
- 4.3 Integrated Systems Biology Approaches to Drug Target Validation for Specific Clinical Indications 110
- 4.4 Conclusion 123

5 The Development of Herceptin®:

Paving the Way for Individualized Cancer Therapy 127

Thorsten S. Gutjahr and Carsten Reinhardt

- 5.1 Introduction 128
- 5.2 HER2 129
- 5.3 Herceptin Mechanism of Action and Effects on Cellular Processes 130
- 5.4 Preclinical Evidence 131
- 5.5 HER2 Testing as a Prerequisite for Herceptin Therapy: Development of Commercially Available and Validated Testing Methodologies 133
- 5.6 HER2 Testing Algorithm 135
- 5.7 Herceptin in Clinical Use 136
- 5.8 Future Prospects for Herceptin and other Targeted Therapies 143
- 5.9 Herceptin in Early Breast Cancer 143
- 5.10 Herceptin Adjuvant Trials 143
- 5.11 Conclusion 145

siRNA – the Magic Bullet and Other Gene Therapeutical Approaches 151

6 Adenovirus-based Gene Therapy: Therapeutic Angiogenesis with Adenovirus 5 Fibroblast Growth Factor-4 (Ad5FGF-4) in Patients with Chronic Myocardial Ischemia 151

Michael McCaman, Francisco J. Castillo, Farah Fawaz, Yasushi Ogawa, Erik Whiteley, Elisabeth Lehmborg, Mei Tan, Jacob Kung, Bruce Mann, Erno Pungor Jr., and Gabor M. Rubanyi

- 6.1 Introduction 152
- 6.2 Therapeutic Angiogenesis and the Importance of Collateral Vessels 153
- 6.3 Designing an Intervention Suitable for Therapeutic Angiogenesis 153
- 6.4 Production and Characterization of the Ad5FGF-4 Vector 156
- 6.5 Pre-clinical Efficacy and Safety of Ad5FGF-4 in Pigs 172
- 6.6 Clinical Studies 175
- 6.7 Summary and Conclusions 178

7 MIDGE Vectors and dSLIM Immunomodulators:

DNA-based Molecules for Gene Therapeutic Strategies 183

Manuel Schmidt, Barbara Volz, and Burghardt Wittig

- 7.1 Vectors for Gene Therapy 184
- 7.2 Immunomodulatory Molecules 193
- 7.3 Application of MIDGE Vectors and dSLIM Immunomodulators 198

8	Nonprotein-coding RNAs and their Potential as Biopharmaceuticals	213
	<i>Maciej Szymanski, Jan Barciszewski and Volker A. Erdmann</i>	
8.1	Introduction	213
8.2	The Contents of the Genomes	214
8.3	npcRNAs	215
8.4	Functions of npcRNAs	217
8.5	npcRNAs and Human Diseases	219
8.6	miRNAs	222
8.7	Future Prospects	223
9	Double-stranded Decoy Oligonucleotides as new Biopharmaceuticals	229
	<i>Andreas H. Wagner and Heiko E. von der Leyen</i>	
9.1	Introduction	230
9.2	Therapeutic Decoy ODN Application	232
10	Rational siRNA Design for RNA Interference: Optimizations for Therapeutic Use and Current Applications	243
	<i>Anastasia Khvorova, Queta Boese, and William S. Marshall</i>	
10.1	RNAi: History and Mechanism	244
10.2	Early siRNA Design Parameters	248
10.3	Current siRNA Design Considerations	251
10.4	Therapeutic Applications of RNAi	259
10.5	Summary: The Future of RNAi in Biopharmaceutical Development	264
	Mobilis in Mobile – Human Embryonic Stem Cells and Other Sources for Cell Therapy	269
11	The First Cloned Human Embryo: An Unlimited Source of Stem Cells for Therapeutic Cloning	269
	<i>Woo Suk Hwang, Byeong Chun Lee, Sung Keun Kang, and Shin Yong Moon</i>	
11.1	Introduction	270
11.2	Human Somatic Cell Nuclear Transfer (SCNT)	270
11.3	Establishment and Characterization of Human SCNT ES Cells	276
11.4	Reprogramming Adult Cells into an Embryonic State	277
11.5	Discussion and Conclusion	279
12	Myocardial Regeneration Strategies using Human Embryonic Stem Cells	283
	<i>Izhak Kehat, Oren Caspi, and Lior Gepstein</i>	
12.1	Introduction	284
12.2	Derivation of Human Embryonic Stem Cells	286
12.3	Cardiomyocyte Differentiation of ES Cells	289
12.4	Possible Research and Clinical Applications of the hES-derived Cardiomyocytes	293
12.5	Early Cardiac Lineage Differentiation	293
12.6	Myocardial Regeneration Strategies using hES-derived Cardiomyocytes	295

- 12.7 Functional Integration of the Cell Grafts 296
- 12.8 Cardiomyocyte Enrichment, Purification, and Up-scaling Strategies 298
- 12.9 Prevention of Immunological Rejection 299
- 12.10 Conclusions 300
- 13 Gene and Cell-based Therapies for Cardiovascular Disease 305**
Abeel A. Mangi
- 13.1 Introduction 306
- 13.2 Gene Therapy as Novel Drug Delivery 306
- 13.3 Cell-based Gene Therapy and Regenerative Cardiovascular Medicine 319
- 13.4 Future Directions and Challenges 321
- 14 Spheramine®: A Cell Therapeutic Approach to Parkinson's Disease 325**
Elke Reissig, Hermann Graf, and Friedrich-Joachim Kapp
- 14.1 Introduction 326
- 14.2 PD 326
- 14.3 Spheramine 334
- 14.4 Randomized, Double-blind, Placebo-controlled Multicenter Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally into the Postcommissural Putamen of Patients with Advanced PD 343
- 14.5 Summary and Outlook 348
- 15 Applying Human Cells to Organogenesis and Transplantation 353**
Benjamin Dekel and Yair Reisner
- 15.1 Growing Demands for Kidney Allograft Transplantation 354
- 15.2 Alternative Sources for Human Renal Allografts 354
- 15.3 Conclusions 367

Volume 2

Part II Biopharmaceuticals and Their Mode of Action

Quid pro Quo – Lysis vs. Coagulation in the Fine-tuned Balance of the Clotting Cascade 377

- 1 Mechanisms of Serine Proteinase Activation: Insights for the Development of Biopharmaceuticals for Coagulation and Fibrinolysis 377**
Rainer Friedrich
- 1.1 Introduction 378
- 1.2 Bacterial Activators of Host Zymogens 381
- 1.3 Some Remarks on Nonproteolytic Activators 388
- 2 Application of the Principle of Polyvalency to Protease Inhibition 395**
Luis Moroder
- 2.1 Introduction 395

2.2	Thermodynamic Model of Bivalent Ligand Binding	396
2.3	Homo- and Heterobivalent Inhibitors of the Yeast 20S Proteasome	398
2.4	Bivalent Inhibition of Mast Cell β -Tryptase	405
2.5	Heterobivalent Inhibition of Thrombin	411
2.6	Perspectives	414
3	A New Technology Standard for Safety and Efficacy in Factor VIII Replacement Therapy: Designing an Advanced Category rFVIII Concentrate	419
	<i>Norbert Riedel and Friedrich Dorner</i>	
3.1	Introduction	420
3.2	Development of rFVIII	428
3.3	Production of rFVIII	430
3.4	Pathogen Safety	433
3.5	Quality Control	435
3.6	Purity and Potency	435
3.7	Preclinical Studies	436
3.8	Clinical Studies	439
3.9	Summary	447
	Errare Humanum Est – What Causes Cancer and How to Selectively Fight Tumors	451
4	Biopharmaceutical Drugs from Natural Sources	451
	<i>David J. Newman, Gordon M. Cragg, and Barry R. O’Keefe</i>	
4.1	Biotechnologically Produced Proteins and Peptides as Approved Drugs	452
4.2	Potential Agents from Non-mammalian Sources as Leads to Novel Therapies	481
4.3	Overall Concluding Comments	488
5	Biopharmaceuticals as Targeting Vehicles for <i>In situ</i> Radiotherapy of Malignancies	497
	<i>Raymond M. Reilly</i>	
5.1	Introduction	498
5.2	Principles of Targeted <i>In situ</i> Radiotherapy of Malignancies	499
5.3	RIT of Non-Hodgkin’s B-Cell Lymphomas: The Pre-eminent Success Story	500
5.4	Other Strategies for <i>In situ</i> Radiotherapy of Non-Hodgkin’s Lymphoma	505
5.5	Radioimmunotherapy of AML: Success but not Cure	505
5.6	RIT of Solid Tumors: Encouraging Results n Minimal Residual Disease	507
5.7	Pre-Targeting Strategies: Improving the Therapeutic Index of RIT	511
5.8	Peptide-Directed <i>In situ</i> Radiotherapy: Targeting Somatostatin Receptors	516
5.9	Auger Electron Radiotherapy: Anti-tumor Effects at the Single Cell Level	519
5.10	α -Particle RIT: Anti-tumor Effects at the Multi-cell Level	525
5.11	Conclusion	526

6	New Directions in Tumor Therapy – Amino Acid Depletion with GlutaDON® as Treatment for Cancer	537
	<i>Rolf Kalhammer and Natarajan Sethuraman</i>	
6.1	Rationale for GlutaDON® Therapy	537
6.2	Preclinical Studies	539
6.3	PEGylation and Protection from Inactivation	541
6.4	Toxicology	545
6.5	Clinical Trial	545
6.6	Summary and Conclusions	546
	Mundus Vult Decipi – High Mutation Rates of HIV and New Paradigms for Treatment	549
7	AIDS Gene Therapy: A Vector Selectively Able to Destroy Latently HIV-1-infected Cells	549
	<i>Francisco Luque Vázquez and Ricardo Oya</i>	
7.1	The Genes and Life Cycle of HIV-1	551
7.2	Gene Therapy of AIDS	553
7.3	Viral Latency: the Real Challenge	557
7.4	A Vector Able Selectively to Destroy Latently Infected Cells	559
8	Combinatorial RNA-based Therapies for HIV-1	569
	<i>Kevin V. Morris and John J. Rossi</i>	
8.1	Introduction	569
8.2	RNA-based Antiviral Agents	570
8.3	RNAi: Diversity of Viral Targets	571
8.4	Delivery of siRNAs to Target Cells	573
8.5	Challenges for RNA-based Therapies	577
8.6	Summary and Conclusion	577
	Part III Improving the Development of Biopharmaceuticals	
	Citius, Altius, Fortius – Acceleration by High Throughput and Ultra-HT	583
1	Design of Modern Biopharmaceuticals by Ultra-high-throughput Screening and Directed Evolution	583
	<i>Markus Rarbach, Wayne M. Coco, Andre Koltermann, Ulrich Ketting, and Manfred Eigen</i>	
1.1	Modern Biopharmaceuticals	584
1.2	Directed Evolution Fundamentals	585
1.3	Generation of Protein Diversity	586
1.4	Selection Strategies	593
1.5	High-throughput and High-content Screening of Protein Libraries	594
1.6	Directed Evolution of Biopharmaceuticals	598
1.7	Conclusions	601

- 2 Learning from Viruses: High-throughput Cloning using the Gateway® System to Transfer Genes without Restriction Enzymes 605**
Jonathan D. Chesnut
- 2.1 Introduction 605
- 2.2 Background 606
- 2.3 Engineering the Lambda System to Create Gateway 609
- 2.4 The Gateway Reactions 610
- 2.5 Creating Gateway Entry Clones 611
- 2.6 Gateway Destination Vectors 613
- 2.7 Applications Enabled by Gateway Cloning 614
- 2.8 HTP Expression Analysis in Mammalian Cells 614
- 2.9 HTP Cloning and Expression in a Baculovirus System 615
- 2.10 Multisite Gateway 616
- 2.11 Creation of Entry Vectors and Three-fragment Multisite Assembly Reaction 618
- 2.12 Perspective 621
- In Vivo Veritas – Early Target Validation in Knock-out Mice and More 621**
- 3 Target Validation: An Important Early Step in the Development of Novel Biopharmaceuticals in the Post-genomic Era 621**
Christoph P. Bagowski
- 3.1 Introduction 622
- 3.2 RNA- and DNA-based Techniques for Post-transcriptional Regulation of Molecular Targets, and their Potential as Biopharmaceutical Drugs 624
- 3.3 Peptide and Protein-based Approaches 636
- 3.4 Protein Kinases as Targets for Drug Development 639
- 3.5 Cell-based Assays for *In vitro* Target Validation in the Drug Discovery Process 640
- 3.6 Animal Models as the Ultimate Target Validation 645
- 3.7 Summary and Conclusions 645
- 4 Genetically Modified Mice in Medical and Pharmaceutical Research 649**
Cord Brakebusch
- 4.1 Disease-oriented Research in Genetically Modified Mice 649
- 4.2 Generation of Genetically Modified Mice by Gene Targeting 651
- 4.3 Analysis of Genetically Modified Mice 659
- 4.4 Alternative Methods 659
- 5 An NIH Model Organism for Biopharmaceutical and Biomedical Research: The Lower Eukaryote *Dictyostelium discoideum* 661**
Thomas Winckler, Ilse Zündorf, and Theodor Dingermann
- 5.1 Introduction 664
- 5.2 The Gene Discovery Tool Box or *Dictyostelium* Research 665
- 5.3 Production of Recombinant Proteins in *D. discoideum* 672

- 5.4 *Dictyostelium discoideum* in Biomedical Research 685
- 5.5 Conclusions 689

Revolution by Evolution – Rational Design for Desire and Scientific Art of Optimization 695

- 6 Releasing the Spring: Cofactor- and Substrate-assisted Activation of Factor IXa 695**
Hans Brandstetter and Katrin Sichler
 - 6.1 Introduction 695
 - 6.2 The Zymogen Form of fIX is Fully Inactive 697
 - 6.3 Relevance of Tyr99 on the Stability of the 99-loop 697
 - 6.4 Lys98 Hinders Substrate Binding to fIXa both Sterically and Electrostatically 698
 - 6.5 Tyr177 Locks the 99-loop in an Inactive Conformation, which is Released by Cofactor fVIIIa and Modified by the Physiologic Substrate fX 699
 - 6.6 S1 Site Mutations Decrease the Activity of fIXa 699
 - 6.7 Evolutionary Relation of fIXa and fXa is Reflected in the Dependence of Activity Changes on Arg/Lys Substrates 700
 - 6.8 By Binding at the 60-loop Ethylene Glycol Indirectly Reorganizes the 99-loop and Allosterically Stimulates the Activity of fIXa 700
 - 6.9 Summary and Conclusion 701
- 7 Accelerating Diagnostic Product Development Process with Molecular Rational Design and Directed Evolution 703**
Harald Sobek, Rainer Schmuck, and Zhixin Shao
 - 7.1 Introduction 704
 - 7.2 Strategies for Optimizing Diagnostic Proteins 705
 - 7.3 Examples 709
 - 7.4 Summary 717

Volume 3

Part IV Production of Biopharmaceuticals

The Industry's Workhorses – Mammalian Expression Systems 723

- 1 Manufacture of Recombinant Biopharmaceutical Proteins by Cultivated Mammalian Cells in Bioreactors 723**
Florian M. Wurm
 - 1.1 Introduction 724
 - 1.2 Vectors, Transfections, and Cell Line Generation 727
 - 1.3 Host Cell Engineering 731
 - 1.4 Gene Transfer and Gene Amplification in Mammalian Cells 733
 - 1.5 Production Principles for Mammalian Cells: Anchorage-dependent Cultures and Suspension Cultures 737
 - 1.6 Large-scale Transient Expression 744

1.7	Regulatory Issues	745
1.8	Concluding Remarks	751
2	Alternative Strategies and New Cell Lines for High-level Production of Biopharmaceuticals	761
	<i>Thomas Rose, Karsten Winkler, Elisabeth Brundke, Ingo Jordan and Volker Sandig</i>	
2.1	Mammalian Cells as a Workhorse to Produce Protein-based Biopharmaceuticals	761
2.2	The Cell Line of Choice	762
2.3	Pushing Expression Levels – Impact of Vector Design and Cell Clone Selection	764
2.4	A Single CHO High-producer Clone for Multiple Products	766
2.5	The G-line: Use of the Immunoglobulin Locus of a Human/Mouse Heterohybridoma for Heterologous Gene Expression	769
2.6	Human Designer Cell Lines	774
2.7	Summary and Conclusion	776
3	PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins	779
	<i>Chris Yallop, John Crowley, Johanne Cote, Kirsten Hegmans-Brouwer, Fija Lagerwerf, Rodney Gagne, Jose Coco Martin, Nico Oosterhuis, Dirk-Jan Opstelten, and Abraham Bout</i>	
3.1	Introduction	780
3.2	Generation of PER.C6 Cells	782
3.3	PER.C6 Cells for the Manufacture of Recombinant Proteins	784
3.4	Fed-batch Process Development	789
3.5	Operation of PER.C6 Cells in Continuous Perfusion	794
3.6	Characterization of Antibodies Produced by PER.C6 Cells	797
3.7	Conclusion	803
4	Use of the Glutamine Synthetase (GS) Expression System for the Rapid Development of Highly Productive Mammalian Cell Processes	809
	<i>John R. Birch, David O. Mainwaring, and Andrew J. Racher</i>	
4.1	Introduction	809
4.2	Cell Line Construction and Selection	810
4.3	Cell Line Stability	818
4.4	Cell Engineering to Increase Productivity	819
4.5	Selection of Useful Cell Sub-populations	822
4.6	Process Development	823
4.7	Summary	830
	Vivat, Crescat, Floreat – A Ripe and Blooming Market for Transgenic Animals and Plants	833
5	Biopharmaceuticals Derived from Transgenic Plants and Animals	833
	<i>Julio Baez</i>	
5.1	Introduction	834

- 5.2 Advantages and Disadvantages of Transgenic Systems for the Production of Biopharmaceuticals 845
- 5.3 Commercial Biopharmaceuticals with Human Clinical Experience for Therapeutic, Immunoprophylactic, and Medical Device Use derived from Transgenic Systems 852
- 5.4 Conclusions 873

- 6 Production of Recombinant Proteins in Plants 893**
Victor Klimyuk, Sylvestre Marillonnet, Jörg Knäblein, Michael McCaman, and Yuri Gleba
- 6.1 Introduction 893
- 6.2 Plant-based Expression Systems 894
- 6.3 Plant-made Recombinant Proteins available Commercially, and under Development 903
- 6.4 Comparative Analysis of the Expression Systems and Production Platforms 907
- 6.5 Summary and Conclusion 909

- 7 Humanized Glycosylation: Production of Biopharmaceuticals in a Moss Bioreactor 919**
Gilbert Gorr and Sabrina Wagner
- 7.1 Introduction 919
- 7.2 Mosses: Some General Aspects 920
- 7.3 Cell Culture 922
- 7.4 Recombinant Expression 923
- 7.5 N-Glycosylation 924
- 7.6 Conclusions and Outlook 927

- 8 ExpressTec: High-level Expression of Biopharmaceuticals in Cereal Grains 931**
Ning Huang and Daichang Yang
- 8.1 Introduction 931
- 8.2 Development of ExpressTec for High-level Expression of Recombinant Proteins in Cereal Grains 932
- 8.3 High-level Expression of Biopharmaceuticals in Cereal Grain using ExpressTec 938
- 8.4 Impact of Expression Level on the Cost of Goods 945
- 8.5 Perspectives of Expressing Biopharmaceuticals in High Plants 946

- 9 Biopharmaceutical Production in Cultured Plant Cells 949**
Stefan Schillberg, Richard M. Twyman, and Rainer Fischer
- 9.1 Introduction 950
- 9.2 Recombinant Proteins Produced in Plant Cell Suspension Cultures 951
- 9.3 Challenges and Solutions for the Production of Recombinant Proteins 954
- 9.4 Process Engineering 958
- 9.5 Downstream Processing 959

9.6	Regulatory Considerations	960
9.7	Conclusions	961
10	Producing Biopharmaceuticals in the Desert: Building an Abiotic Stress Tolerance in Plants for Salt, Heat, and Drought	967
	<i>Shimon Gepstein, Anil Grover, and Eduardo Blumwald</i>	
10.1	General Comments on Abiotic Stresses	968
10.2	Drought and Salt Tolerance	969
10.3	High-temperature Stress	981
10.4	Conclusions and Perspectives	989
11	The First Biopharmaceutical from Transgenic Animals: ATryn®	995
	<i>Yann Echelard, Harry M. Meade, and Carol A. Ziomek</i>	
11.1	Introduction	996
11.2	Recombinant Production of AT	998
11.3	Characterization of rhAT	1003
11.4	Preclinical Studies	1007
11.5	Clinical Trials with rhAT	1011
11.6	Conclusions	1016
	Alea Non Lacta Est – Improving Established Expression Systems	1021
12	Producing Modern Biopharmaceuticals: The Bayer HealthCare Pharma Experience with a Range of Expression Systems	1021
	<i>Heiner Apeler</i>	
12.1	The <i>Escherichia coli</i> Expression Platform	1022
12.2	The <i>Saccharomyces cerevisiae</i> Expression Platform	1027
12.3	The HKB11 Expression Platform	1029
12.4	Outlook and Conclusion	1031
13	Advanced Expression of Biopharmaceuticals in Yeast at Industrial Scale: The Insulin Success Story	1033
	<i>Asser Sloth Andersen and Ivan Diers</i>	
13.1	Introduction	1033
13.2	Design and Optimization of the Insulin Precursor Molecule	1036
13.3	Production of Insulin	1041
13.4	Conclusions and Future Aspects	1042
14	Baculovirus-based Production of Biopharmaceuticals using Insect Cell Culture Processes	1045
	<i>Wilfried Weber and Martin Fussenegger</i>	
14.1	Introduction	1045
14.2	Molecular Tools for the Construction of Transgenic Baculoviruses	1046
14.3	Insect Cell Culture	1047
14.4	Insect Cell Glycosylation and Glycoengineering	1047

- 14.5 Nutrient and Kinetic Considerations for Optimized BEVS-based Protein Production 1048
- 14.6 Scaling-up Baculovirus-based Protein Production 1050
- 14.7 Generic Protocol of Optimized Protein Production 1050
- 14.8 Case study: Rapid Optimization of Expression Conditions and Large-scale Production of a Brutons Tyrosine Kinase Variant (BTK) 1053
- 14.9 Conclusion 1058

- 15 Robust and Cost-effective Cell-free Expression of Biopharmaceuticals: *Escherichia Coli* and Wheat Embryo 1063**
Luke Anthony Miles
- 15.1 Introduction 1064
- 15.2 Transcription 1066
- 15.3 Translational 1068
- 15.4 Treatment of Extracts for Synthesis of Disulfide-bonded Proteins 1072
- 15.5 ATP Regeneration Systems 1074
- 15.6 Reaction Conditions 1075
- 15.7 Conclusion 1079

- When Success Raises its Ugly Head – Outsourcing to Uncork the Capacity Bottleneck 1083**

- 16 Contract Manufacturing of Biopharmaceuticals Including Antibodies or Antibody Fragments 1083**
J. Carsten Hempel and Philipp N. Hess
- 16.1 Introduction 1084
- 16.2 Expression Systems and Manufacturing Procedures 1085
- 16.3 Outsourcing and Contract Manufacturing 1089
- 16.4 Summary and Outlook 1100

- Part V Biopharmaceuticals used for Diagnostics and Imaging**

- From Hunter to Craftsman – Engineering Antibodies with Nature’s Universal Toolbox 1105**

- 1 Thirty Years of Monoclonal Antibodies: A Long Way to Pharmaceutical and Commercial Success 1105**
Uwe Gottschalk and Kirsten Mundt
- 1.1 Introduction 1107
- 1.2 Making Monoclonal Antibodies 1109
- 1.3 Other Antibody Formats: Antibody Fragments 1113
- 1.4 Medical Application Areas for MAbs 1116
- 1.5 From Initial Failure to Success: Getting the Target Right 1117
- 1.6 The Market Perspective 1119
- 1.7 Drug Targeting: The Next Generation in Cancer Treatment 1122
- 1.8 Developing a Manufacturing Process for MAbs 1126
- 1.9 Routine Manufacture of MAbs 1127

- 1.10 Glycosylation and Other Post-translational Modifications 1132
- 1.11 Emerging Issues in MAb Production 1134
- 1.12 The Future of MAbs 1136

- 2 Modern Antibody Technology: The Impact on Drug Development 1147**
Simon Moroney and Andreas Plückthun
- 2.1 Introduction 1147
- 2.2 Immunogenicity 1148
- 2.3 Technology 1153
- 2.4 Reaching the Target: The Importance of Specificity, Affinity and Format 1163
- 2.5 Exerting an Effect at the Target 1168
- 2.6 Antibodies in their Natural Habitat: Infectious Diseases 1175
- 2.7 Opportunities for New Therapeutic Applications Provided by Synthetic Antibodies 1176
- 2.8 Future Directions and Concluding Statements 1177

- 3 Molecular Characterization of Autoantibody Responses in Autoimmune Diseases: Implications for Diagnosis and Understanding of Autoimmunity 1187**
Constanze Breithaupt
- 3.1 Autoantibodies in Autoimmune Diseases 1188
- 3.2 Autoantibody Epitopes 1190
- 3.3 Visualization of Epitopes 1195
- 3.4 Structural Characterization of Autoantibody–Autoantigen Complexes 1199
- 3.5 Conclusions 1205

- Find, Fight, and Follow – Target-specific Troika from Mother Nature’s Pharmacopoeia 1211**

- 4 Molecular Imaging and Applications for Pharmaceutical R&D 1211**
Joke G. Orsel and Tobias Schaeffter
- 4.1 Introduction 1212
- 4.2 Imaging Modalities and Contrast Agents 1213
- 4.3 Molecular Imaging 1225
- 4.4 Molecular Imaging for Drug Discovery and Development 1230
- 4.5 Concluding Remarks 1239

- 5 Design and Development of Probes for *In vivo* Molecular and Functional Imaging of Cancer and Cancer Therapies by Positron Emission Tomography (PET) 1243**
Eric O. Aboagye
- 5.1 What is Positron Emission Tomography? 1244
- 5.2 Radiochemistry Considerations 1246
- 5.3 Pharmacological Objectives in Oncology Imaging Studies 1249
- 5.4 The Use of Radiolabeled Drugs to Image Tumor and Normal Tissue Pharmacokinetics 1250

5.5	Pharmacodynamic Studies	1254
5.6	Conclusions	1264
6	Ligand-based Targeting of Disease: From Antibodies to Small Organic (Synthetic) Ligands	1271
	<i>Michela Silacci and Dario Neri</i>	
6.1	Introduction	1272
6.2	Ligands	1273
6.3	Classes of Diseases	1276
6.4	From a Ligand to a Product	1288
6.5	Concluding Remarks	1289
7	Ultrasound Theranostics: Antibody-based Microbubble Conjugates as Targeted <i>In vivo</i> Contrast Agents and Advanced Drug Delivery Systems	1301
	<i>Andreas Briel, Michael Reinhardt, Mathias Mäurer, and Peter Hauff</i>	
7.1	Motivation: “Find, Fight and Follow!”	1302
7.2	Ultrasound: “Hear the Symptoms”	1304
7.3	Ultrasound Contrast: “Tiny Bubbles”	1305
7.4	The Perfect Modality: “Sensitive Particle Acoustic Quantification (SPAQ)”	1308
7.5	Targeting and Molecular Imaging: “The Sound of an Antibody”	1309
7.6	Drug Delivery: “The Magic Bullet”	1315
7.7	Ultrasound, Microbubbles and Gene Delivery: “Noninvasive Micro-Gene Guns”	1318
7.8	Summary: Ultrasound Theranostics “Building a Bridge between Therapy and Diagnosis”	1320
	Getting Insight – Sense the Urgency for Early Diagnostics	1325
8	Development of Multi-marker-based Diagnostic Assays with the ProteinChip® System	1325
	<i>Andreas Wiesner</i>	
8.1	The Urgency of Earlier Diagnosis	1326
8.2	Proteins are Best Choice Again	1327
8.3	Current Tools for Protein Biomarker Detection	1328
8.4	The ProteinChip® System at a Glance	1329
8.5	Distinctions of the SELDI Process	1333
8.6	The Pattern Track™ Process: From Biomarker Discovery to Assay Development	1334
8.7	Protein Variants as Disease Markers	1337
8.8	Conclusion and Outlook	1338
9	Early Detection of Lung Cancer: Metabolic Profiling of Human Breath with Ion Mobility Spectrometers	1343
	<i>Jörg Ingo Baumbach, Wolfgang Vautz, Vera Ruzsanyi, and Lutz Freitag</i>	
9.1	Introduction	1343

- 9.2 Material and Methods: IMS 1345
- 9.3 Results and Discussion 1347
- 9.4 Clinical Study 1349
- 9.5 Conclusions 1354

Volume 4

Part VI Advanced Application Routes for Biopharmaceuticals

Getting Inside – Quest for the Best and How to Improve Delivery 1361

- 1 Advanced Drug Delivery Systems for Biopharmaceuticals 1361**
Gesine E. Hildebrand and Stephan Harnisch
- 1.1 Introduction 1362
- 1.2 Challenges for the Administration of Biopharmaceuticals 1363
- 1.3 Drug Delivery Strategies 1366
- 1.4 Outlook 1384

Pathfinder – New Ways for Peptides, Proteins and Co 1393

- 2 Poly(ethylene) Glycol Conjugates of Biopharmaceuticals in Drug Delivery 1393**
Michael D. Bentley, Mary J. Bossard, Kevin W. Burton, and Tacey X. Viegas
- 2.1 Introduction 1394
- 2.2 The Polymer 1394
- 2.3 Safety and Disposition of PEG 1396
- 2.4 PEG Reagents and Conjugation 1397
- 2.5 Biopharmaceutical Conjugates 1400
- 2.6 PEGylation of Peptides 1407
- 2.7 Formulations of PEGylated Biopharmaceuticals 1408
- 2.8 Analysis of PEG-conjugates 1411
- 2.9 Summary and Future Outlook 1415
- 3 Novel Vaccine Adjuvants Based on Cationic Peptide Delivery Systems 1419**
Karen Lingnau, Christoph Klade, Michael Buschle, and Alexander von Gabain
- 3.1 Vaccines and their Importance in the Fight against Human Diseases 1420
- 3.2 Adjuvants: An Overview 1423
- 3.3 Cationic Peptides as Novel Vaccine Adjuvants 1426
- 3.4 Cationic Antimicrobial Peptides (CAMP) as Novel Adjuvants 1433
- 3.5 Cationic Peptide Delivery Systems in Combination with Other Adjuvants 1437
- 3.6 The Development of IC31 and Future Prospects 1440
- 3.7 Conclusions 1440

- 4 The Evolving Role of Oralin™ (Oral Spray Insulin) in the Treatment of Diabetes using a Novel RapidMist™ Diabetes Management System 1445**
Pankaj Modi
- 4.1 Introduction 1446
- 4.2 Rationale for Oralin™ Development 1446
- 4.3 The Benefits of Oralin™ 1447
- 4.4 The Preparation and Pharmaceutical Properties of Oralin™ 1448
- 4.5 Phase II, Long-term Safety and Efficacy Study 1457
- 4.6 Conclusions 1460
- 5 Improvement of Intestinal Absorption of Peptide and Protein Biopharmaceuticals by Various Approaches 1463**
Akira Yamamoto
- 5.1 Improvement of Peptide and Protein Absorption 1464
- 5.2 Use of Protease Inhibitors 1467
- 5.3 Chemical Modification of Peptide and Protein Biopharmaceuticals 1472
- 5.4 Chitosan Capsules for the Colon-specific Delivery of Insulin 1480
- 5.5 Conclusion 1484
- Via Mala – the Stoney Road of DNA Delivery: Back-pack, Feed-back, and Pay-back 1487**
- 6 DNA Vaccine Delivery from Poly(ortho ester) Microspheres 1487**
Chun Wang, Herman N. Eisen, Robert Langer, and Jorge Heller
- 6.1 Introduction 1488
- 6.2 Poly(Ortho Esters) 1494
- 6.3 Preparation and Characterization of Microspheres 1496
- 6.4 *In vivo* Evaluation of Immune Responses 1500
- 6.5 Concluding Remarks 1503
- 7 Liposomal *In vivo* Gene Delivery 1507**
Shigeru Kawakami, Fumiyoshi Yamashita, and Mitsuru Hashida
- 7.1 Cationic Charge-mediated *In vivo* Gene Transfer to the Lung 1510
- 7.2 Asialoglycoprotein Receptor-mediated *In vivo* Gene Transfer to Hepatocytes 1512
- 7.3 Mannose Receptor-mediated *In vivo* Gene Transfer to Macrophages 1513
- 7.4 Folate Receptor-mediated *In vivo* Gene Transfer to Cancer Cells 1515
- 7.5 Transferrin Receptor-mediated *In vivo* Gene Transfer to Brain 1517
- 7.6 Conclusions 1517
- 8 Programmed Packaging:
A New Drug Delivery System and its Application to Gene Therapy 1521**
Kentaro Kogure, Hidetaka Akita, Hiroyuki Kamiya, and Hideyoshi Harashima
- 8.1 New Concept for Gene Delivery 1521
- 8.2 Controlled Intracellular Trafficking 1525

- 8.3 Transgene Expression and Gene Correction 1531
- 8.4 Towards Clinical Applications of Transgene Expression and Gene Correction 1534

Getting Beyond – Rocket Science vs. Science Fiction 1537

- 9 Bionanotechnology and its Role to Improve Biopharmaceuticals 1537**
Oliver Kayser
- 9.1 Introduction 1537
- 9.2 Drug and Gene Delivery 1539
- 9.3 Gene Delivery 1543
- 9.4 Biosensors 1544
- 9.5 Implants and Tissue Engineering 1546
- 9.8 Safety Aspects 1548
- 9.7 Conclusions and Future Trends 1550

Part VII From Transcription to Prescription of Biopharmaceuticals

Dosis Facit Venenum – The Therapeutic Window between Systemic Toxicity and Lack of Efficacy 1557

- 1 Analytics in Quality Control and *In vivo* 1557**
Michael Hildebrand
- 1.1 Introduction 1558
- 1.2 Quality Control 1559
- 1.3 Classes of Biopharmaceuticals 1560
- 1.4 Analytical Methods and Specifications 1560
- 1.5 International Guidelines on Quality Control 1571
- 1.6 Analytics *In vivo* 1573
- 1.7 Conclusions 1577
- 2 Design, Development and Optimization: Crystal Structures of Microsomal Cytochromes P450 1581**
Dijana Matak Vinković, Sheena Whyte, Harren Jhoti, Jose Cosme, and Pamela A. Williams
- 2.1 P450: The Background 1581
- 2.2 Importance of P450s for Drug Development 1582
- 2.3 Variability and Drug Metabolism 1583
- 2.4 The Structure of Cytochrome P450 1584
- 2.5 Conclusions 1599
- 3 Mettox™: A Suite of Predictive *In silico* and *In vitro* Assays for Metabolic and Genotoxicological Profiling of Preclinical Drug Candidates 1603**
Michael Murray
- 3.1 Issues and Economics of Early ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Assessment 1604

3.2	Phase I Metabolism Prediction: Computational Approaches	1608
3.3	Phase I Metabolism Prediction: <i>In vitro</i> Techniques	1613
3.4	Genotoxicity Prediction	1624
3.5	Conclusions	1634
	Happy End: Claim to Fame and Approval	1637
4	Considerations for Developing Biopharmaceuticals: FDA Perspective	1637
	<i>Kurt Brorson, Patrick G. Swann, Janice Brown, Barbara Wilcox, and Marjorie A. Shapiro</i>	
4.1	Introduction	1638
4.2	Regulatory Authority	1639
4.3	Overview of Product Development: CMC Perspective	1643
4.4	Chemistry, Manufacturing and Controls Considerations	1645
4.5	Quality Control and Assurance	1647
4.6	Microbial Issues Specific to Biopharmaceuticals	1650
4.7	Process Validation	1653
4.8	Inspectional Considerations	1653
4.9	Biotech Development: Lessons Learned and Issues Overcome by Industry and FDA	1654
4.10	FDA Initiatives to Improve the Pharmaceutical and Biopharmaceutical Development Process	1661
5	The Regulatory Environment for Biopharmaceuticals in the EU	1669
	<i>Axel F. Wenzel and Carina E. A. Sonnega</i>	
5.1	Introduction	1673
5.2	History and Background	1673
5.3	The Competent Regulatory Bodies	1676
5.4	What is the EU Authorities' Definition of a Biotechnological Product?	1681
5.5	The Regulatory Framework	1682
5.6	CP: The "Biotech" Procedure	1683
5.7	From Transcription to Prescription: What is Different for Biotechnological Drugs?	1688
5.8	Biogenerics	1700
5.9	Conclusions and Outlook	1701
	Part VIII From Bench to Bedside – The Aftermaths	
	Think Big and Dealmaking for Growth – Global Changes in the Health-care Sector	1711
1	Healthcare Trends and their Impact on the Biopharmaceutical Industry: Biopharmaceuticals Come of Age	1711
	<i>Alexander Moscho, Markus A. Schäfer, and Kristin Yarema</i>	
1.1	Introduction	1712
1.2	Despite Robust Demand the Industry Faces Severe Challenges	1713

- 1.3 Why Biopharmaceuticals can Succeed in Rougher Markets 1724
- 1.4 Biopharmaceutical Players Will Need to Adapt their Portfolios and Business Models 1728
- 1.5 Conclusions and Outlook 1738

News and Views – Quo Vadis, Biopharmaceuticals? 1741

2 mondoBIOTECH: The Swiss biotech BOUTIQUE 1741

Dorian Bevec and Fabio Cavalli

- 2.1 Introduction
- 2.2 Product Platforms 1742
- 2.3 Interferon- γ + Genechip 1750
- 2.4 Bacteriophages 1751
- 2.5 Outlook for the Company 1752

3 G-CSF and Bioequivalence: The Emergence of Healthcare Economics 1755

James Harris, III

- 3.1 Introduction 1756
- 3.2 Biogenerics and Bioequivalence 1756
- 3.3 Summary and Outlook 1767

Light at the End of the Tunnel or Back to the Roots? 1771

4 Bioinformatics: From Peptides to Profiled Leads 1771

Paul Wrede and Matthias Filter

- 4.1 Introduction 1772
- 4.2 Basic Concepts of Virtual Drug Discovery 1773
- 4.3 Pep2Lead Concept 1778
- 4.4 ADMETox Profiling 1785
- 4.5 Outlook 1798

5 Engineering and Overproduction of Polyketide Natural Products 1803

Martha Lovato Tse and Chaitan Khosla

- 5.1 Introduction 1804
- 5.2 Polyketide Synthases 1806
- 5.3 Engineering PKSs to Produce Novel Polyketides 1815
- 5.4 Development of Scalable Production Processes 1820
- 5.5 Conclusions 1825

Epilog 1833

More about the Editor 1835

Supplement CD-ROM 1837

Subject Index 1841